Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetics and Anti-VEGF Response in wAMD
NCT06952452Phase 3Recruiting
- Sponsor
- Parc de Salut Mar
- Start
- Nov 2022
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in exudative macular degeneration, sponsored by Parc de Salut Mar. Started Nov 2022; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06952452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952452.